- Abstract Number: 1671
Laboratory Investigation Results Influence Physician’s Global Assessment of Disease Activity in Systemic Lupus Erythematosus
- Abstract Number: 1270
Lack of Association of Comorbidities with Ultrasonographic Urate Deposition in Asymptomatic Hyperuricemia
- Abstract Number: 1581
Lack of Specificity in Testing for Murine Tissue Specific Autoantibodies for the Diagnosis of Sjogren’s Syndrome
- Abstract Number: 1562
Large Granular Lymphocyte Proliferations in Primary Sjögren’s Syndrome: An Iatrogenic Manifestation
- Abstract Number: 2055
Laser Capture Microdissection to Interrogate B Cells in RA Synovial Tissue
- Abstract Number: 1620
Lateral DXA More Effective in Detecting Osteoporosis Than Conventional DXA in Axial Spondyloarthropathy
- Abstract Number: PP06
Learning to Self-Advocate in the Transition from Pediatric to Adult Lupus Care
- Abstract Number: 2747
Leflunomide and Methotrexate in Treatment of Giant Cell Arteritis: Comparison of Efficacy, Safety and Drug Survival
- Abstract Number: 551
Leflunomide As a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
- Abstract Number: 2843
Leflunomide in Giant Cell Arteritis and Polymyalgia Rheumatica: A Real World Single Centre Experience
- Abstract Number: 974
Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis: A Prospective, Multicenter, Randomized, Open-Label Clinical Trial
- Abstract Number: 1798
Leg Ulcers in Behçet’s Syndrome: An Observational Survey in 24 Patients
- Abstract Number: 2977
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces T-Cell Population and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin
- Abstract Number: 1454
Levels of 14-3-3eta Are an Independent Predictor of Long-Term Radiographic Erosive Progression and of Short-Term Rapid Radiographic Erosive Progression in Patients with Inflammatory Polyarthritis
- Abstract Number: 564
Levels of CXCL13 and sICAM1 Correlate with Disease Activity Score in Rheumatoid Arthritis (RA) Patients Treated with Tocilizumab (TCZ)
- Abstract Number: 1973
Leveraging Publicly Available Gene Expression Data and Applying Machine Learning to Identify Novel Biomarkers for Rheumatoid Arthritis
- Abstract Number: 472
Libman Sacks Endocarditis in Pediatric Systemic Lupus Erythematosus: Clinical Features and Complications
- Abstract Number: 2984
Lifestyle and MTX Use Are the Strongest Predictors of Not Achieving Remission in the First Year of Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort (CATCH)
- Abstract Number: 406
Limiting the Risk of Osteoarthritis after Anterior Cruciate Ligament Injury: Are We Missing the Opportunity to Intervene?
- Abstract Number: 1970
Linking Genetics to T Cell Phenotype in JIA: Rationale for IL-2 Therapy
- Abstract Number: 1062
Linking Systemic Angiogenic Markers to Synovial Vascularization in Rheumatoid Arthritis
- Abstract Number: 510
Lipid Profile and Cardiovascular Risk in Subjects at Risk for Rheumatoid Arthritis
- Abstract Number: 1253
Lipid Screening and Treatment Patterns Among Patients with Rheumatic Diseases
- Abstract Number: 1861
Lipid Screening in Medicare Beneficiaries with Rheumatoid Arthritis
- Abstract Number: 2447
Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs
- Abstract Number: 1594
Liver Enzyme Elevation in Patients with Ankylosing Spondylitis Treated with TNF Inhibitor: A Single-Center Historical Cohort Study
- Abstract Number: 2529
Liver Function Test Levels with Sarilumab Treatment in Phase 3 Trials: Analysis By Baseline Liver Function Test (LFT) Level
- Abstract Number: 2234
Liver Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease
- Abstract Number: PP12
Living a Full Life with A.S. Through Adaptations
- Abstract Number: 843
Localization of the Voltage-Gated Sodium Channel 1.7 in Peripheral Monocytes Contributes to Activation of BAFF Signaling in Monocytes of Patients with Primary Sjögren’s Syndrome
- Abstract Number: 850
Long Term Efficacy of Cartilage Repair Induced By scSOX9 in Situ with Bone Marrow-Derived Mesenchymal Stem Cells
- Abstract Number: 2290
Long Term Follow-up Results of Myositis Patients Treated with H. P. Acthar Gel
- Abstract Number: 2781
Long Term Follow-up Results of Takayasu Arteritis Cohort: A Tertiary-Single Center Study
- Abstract Number: 2664
Long-Term Clinical Outcomes in a Cohort of Adults with Childhood-Onset Systemic Lupus Erythematosus
- Abstract Number: 2381
Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years
- Abstract Number: 2577
Long-Term Effect of Ixekizumab on Patient-Reported Outcomes in Patients with Psa and Inadequate Response to TNF Inhibitors: 2-Year Follow-up from a Phase 3 Study
- Abstract Number: 2575
Long-Term Effects of TNF-Alpha Inhibitors on Bone Mineral Density and the Incidence of Vertebral Fractures in Patients with Ankylosing Spondylitis
- Abstract Number: 2271
Long-Term Efficacy and Safety of Adalimumab By Immunosuppressant Use in Patients with Non-Infectious Uveitis
- Abstract Number: 2863
Long-Term Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF (crFMF), Hids/Mkd and TRAPS: Results from the Pivotal Phase 3 Cluster Trial
- Abstract Number: L13
Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial
- Abstract Number: 527
Long-Term Follow up of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis
- Abstract Number: 2606
Long-Term Inhibition of Radiographic Progression with Originator Adalimumab in Patients with Moderate to Severe Psoriatic Arthritis with or without Radiographic Damage at Baseline
- Abstract Number: 2516
Long-Term Maintenance of Response in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol
- Abstract Number: 2779
Long-Term Outcome and Prognostic Factors after Aortic Valve Surgery Due to Aortic Valve Regurgitation in Patients with Takayasu Arteritis
- Abstract Number: 1885
Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger’s disease): A Multicenter Study of 224 Patients
- Abstract Number: 1419
Long-Term Outcome of 50 Patients with Linear Scleroderma Treated with Methotrexate
- Abstract Number: 2429
Long-Term Outcome of Children Born to Mothers with Chronic Arthritis and Exposed to TNF-Inhibitors during Pregnancy: A Case-Control Study
- Abstract Number: 2261
Long-Term Outcome of Pulmonary Sarcoidosis: A Population-Based Cohort Study from 1976-2013
- Abstract Number: 617
Long-Term Outcome of Rituximab in Rheumatoid Arthritis: Real World Experience
- Abstract Number: 980
Long-Term Outcome of Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis:Results of 18-Year Follow-up in the Population-Based Nordic JIA Cohort
- Abstract Number: 1747
Long-Term Outcomes of Patients with Nonsevere Eosinophilic Granulomatosis with Polyangiitis Given Azathioprine and Glucocorticoids for Remission Induction
- Abstract Number: 1749
Long-Term Renal Outcome in Pulmonary-Limited Microscopic Polyangiitis
- Abstract Number: 949
Long-Term Rheumatic and Musculoskeletal Disorders Associated to Ebola Virus Infection
- Abstract Number: 1411
Long-Term Safety of Different Doses of Canakinumab (<2, 2–<4, and 4–<8 mg/kg) in Patients Aged <4–≥65 Years: Results from the β-Confident Registry
- Abstract Number: 904
Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Results of the Four-Year Study of Rituximab in ANCA-Associated Vasculitis Registry
- Abstract Number: 2379
Long-Term Safety of Subcutaneous Tocilizumab Administration in Systemic and Polyarticular Juvenile Idiopathic Arthritis
- Abstract Number: 963
Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program
- Abstract Number: 2527
Long-Term Safety with Sarilumab Plus Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) and Sarilumab Monotherapy in Rheumatoid Arthritis (RA): An Integrated Analysis with 9,000 Patient-Years (Pt-Yrs) of Follow-up
- Abstract Number: 2974
Long-Term Survival in Lung Transplantation for Interstitial Lung Disease Due to Rheumatic Systemic Diseases. Study of 26 Cases of a Single Center
- Abstract Number: 748
Long-Term Survival of Renal Transplantation Due to Lupus Nephritis. Comparative Study with Non-Autoimmune Transplantation. Study from a Single Center
- Abstract Number: 1771
Long-Term Survival of Renal Transplantation in Rapidly Progressive Glomerulonephritis (RPGN). Study of 43 Cases from a Single Center
- Abstract Number: 2509
Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years’ Treatment
- Abstract Number: 1529
Long-Term, Real-World Safety of Adalimumab in Rheumatoid Arthritis
- Abstract Number: 2629
Longitudinal Analysis of Persistent Positivity of Antiphospholipid Antibodies in Systemic Lupus Erythematosus
- Abstract Number: 628
Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database
- Abstract Number: 1406
Longitudinal Construct Validity of the Psaid Individual Items: Can We Eliminate Other Questionnaires If Using the Psaid?
- Abstract Number: 2291
Longitudinal Course of the Disease in Anti-Mi2 Patients: More Intense Muscle Weakness, Good Response to Treatment and Progressive Reduction of Autoantibody Titers
- Abstract Number: 1890
Longitudinal Deep Learning on Electronic Health Record Data to Predict Future Rheumatoid Arthritis Disease Activity
- Abstract Number: 574
Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily
- Abstract Number: 787
Longitudinal Follow-up of Anti-Topoisomerase I Positive Patients within the Leiden Systemic Sclerosis Cohort – Prognosis Infaust?
- Abstract Number: 2944
Longitudinal Outcomes and Predictors of E-Learning Effectiveness in Patients with Axial Spondyloarthritis: A Randomized Controlled Trial
- Abstract Number: 1665
Longitudinal Stratification of Gene Expression Reveals Three SLE Groups of Disease Activity Progression
- Abstract Number: 902
Longitudinal Trends in Clinical Disease Features after Myeloablative Autologous Stem-Cell Transplantation or Cyclophosphamide in Severe Scleroderma
- Abstract Number: 1823
Loss of Synovial Tissue Resident Macrophages Permits Monocyte to Macrophage Differentiation and Inflammation in Hupo Mice
- Abstract Number: 1856
Low Aspirin Use and High Prevalence of Preeclampsia Risk Factors Among Pregnant Women in a Multi-National SLE Inception Cohort
- Abstract Number: 1334
Low Density Granulocytes As Biomarkers of Disease Activity and Damage in Patients with Idiopathic Inflammatory Myopathies
- Abstract Number: 1352
Low Density Granulocytes in Idiopathic Inflammatory Myopathy
- Abstract Number: 2584
Low Incidence of Both New-Onset and Flares of Uveitis in Secukinumab-Treated Patients with Ankylosing Spondylitis: Clinical Trial and Post-Marketing Safety Analysis
- Abstract Number: 562
Low Inflammation on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis That Achieved Sustained Clinical Remission on Adalimumab
- Abstract Number: 499
Low Inflammatory Burden and Statin Exposure Inhibit Progression and Induce Regression of Early Coronary Plaques in Rheumatoid Arthritis
- Abstract Number: 525
Low Interstitial Lung Disease Event Rate in Patients with Rheumatoid Arthritis: Pooled Post Hoc Analysis of Data from the Tofacitinib Clinical Development Program
- Abstract Number: 1857
Low Molecular Weight Heparin and Aspirin Combination Therapy Modulates Th1/Th2 Cell Imbalance in Pregnant Patients with Antiphospholipid Antibody-Associated Recurrent Pregnancy Loss
- Abstract Number: 670
Low Rate of Spinal Radiographic Progression over 2 Years in Ankylosing Spondylitis Patients Treated with Secukinumab: A Historical Cohort Comparison
- Abstract Number: 343
Low Rates of Immunizations in Cohort of Immunocompromised Patients in an Academic Rheumatology Practice
- Abstract Number: 513
Low Serum IGF1 Is Associated with Higher Cardiovascular Morbidity in the Middle-Aged Women with Rheumatoid Arthritis
- Abstract Number: 973
Low-Dose IL-2 Combined with Rapamycin Efficiently Promoted Disease Remission and Recovered the Balance of Th17/Regulatory T Cells in Patients with Refractory Systemic Lupus Erythematosus
- Abstract Number: 1086
Low-Dose IL-2 Combined with Rapamycin Efficiently Promotes Remission of Refractory Systemic Lupus Erythematosus
- Abstract Number: 1583
Low-Dose IL-2 Promotes the Proliferation of Peripheral Regulatory T Cells in Primary Sjogren’s Syndrome to Restore Its Balances with Pro-Inflammatory Lymphocytes
- Abstract Number: 1937
Low-Dose IL-2 Restored Reduced Regulatory T Cells in Patients with Rheumatoid Arthritis
- Abstract Number: 2660
Low-Dose Interleukin-2 Treatment of Refractory Lupus Nephritis
- Abstract Number: 1905
Lower Education Level Is Associated with Higher Risk of Developing Rheumatoid Arthritis
- Abstract Number: 955
Lower Limb Muscle Strength and Protection Against Functional Decline and Structural Worsening in Knee Osteoarthritis
- Abstract Number: 2245
Lubricin/Proteoglycan 4 (PRG4) Inhibits NLRP3 Inflammasome Assembly in Monosodium Urate (MSU)-Crystal Induced Arthritis.
- Abstract Number: 2214
Lung Involvement in Primary Sjögren’s Syndrome: Spectrum of Pulmonary Abnormalities and Computed Tomography Findings
- Abstract Number: 2912
Lupus Flare Activity from the Patient Perspective
- Abstract Number: 474
Lupus Impact Tracker (LIT) As a New Tool in Assessing Patient Reported Outcome in Pediatric Lupus
- Abstract Number: 1675
Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort
- Abstract Number: 1674
Lupus Impact Tracker Validation in a Large European Spanish Lupus Registry Cohort
- Abstract Number: 1896
Lupus Keratinocytes Exhibit Skewed Interferon Responses and Dysregulation of a Novel Regulator of Interferon Signaling
- Abstract Number: 1701
Lupus Low Disease Activity State: Predicting Organ Damage Accrual and Cardiovascular Risk in Patients with Systemic Lupus Erythematosus
- Abstract Number: 92
Lupus Nephritis Serum Induces Neutrophil Chemotaxis Towards Glomerular Endothelial Cells in Vitro
- Abstract Number: 2681
Lupus Primary Care Management Practices
- Abstract Number: 2107
Lupus-Prone SLE1.2.3. Mice Exhibit Loss of Thymus-Derived CD4+CD25+Helios+ Tregs
- Abstract Number: 1990
Luteolin Modulates Glyco-Lipo-Oxidative Protein Modifications and Inhibits Inflammatory Cytokine Release in Human Osteoarthritic Articular Chondrocytes: Comparison with Colchicine
- Abstract Number: 141
Lymphocyte Activation Gene 3 Plasma Level Is Increased and Associated with Progression in Early Rheumatoid Arthritis
- Abstract Number: 88
Lymphocyte DNA Methylation As a Mediator of Genetic Risk in Rheumatoid Arthritis
- Abstract Number: 1122
Lymphocyte Immunophenotypes at Randomization on the Scleroderma: Cyclophosphamide or Transplantation Trial: Comparison of Treatment Naïve and DMARD Treated Participants with Healthy Controls
- Abstract Number: 2265
Lymphocyte Immunophenotyping and CD4/CD8 Ratio in Cerebrospinal Fluid for the Diagnosis of Sarcoidosis-Related Uveitis
- Abstract Number: 2143
Lymphoproliferative Malignancy in Psoriatic Arthritis and the Role of Systemic Immunosuppressive Therapies
2018 ACR/ARHP Annual Meeting
October 19-24, 2018. Chicago, IL.